This week, our President and Managing Director, Jennifer Che, attended the Asia Summit for Global Health at the Hong Kong Convention and Exhibition Centre (HKCEC). She was truly impressed by the variety of health-related start-ups, projects, prototypes, and collaborations showcased at the event. The advancements in therapeutics, traditional Chinese medicine, diagnostics, surgical equipment, robotics, and AI solutions highlighted the dynamic biotech landscape of Hong Kong today—a stark contrast to when she first arrived.

Jennifer particularly noted the remarkable initiatives emerging from the InnoHK Centres, which stem from collaborations between local and international universities. Reflecting on the event, she echoed Nancy Ip's sentiment at the HKUST reception: “We can’t do it alone. The most important thing is to collaborate.” This collaborative spirit is vital for driving innovation and improving global health outcomes.

我们的过去活动

Recommended Insights

China Releases Details on Patent Term Extension, Deferred Examination and More in the Latest Draft Implementation Rules of the New Chinese Patent Law

2020年12月11日
The China National Intellectual Property Administration (CNIPA) is moving forward at breakneck speeds aiming to get all the necessary pieces in place for the June 1, 2021 date when the new 4th Amendment of the Patent Law will come into effect. Most recently, this means a flurry of drafts coming out from CNIPA, including, but […]

China Announcing More Proposed Amendments to the Examination Guidelines in 2022

2022年11月17日
It’s been a year and a half since the new Chinese Patent Law came into effect (1 June 2021). Although various versions of draft Examination Guidelines have been released, thus far no official finalized versions have been confirmed. On October 31, 2022, yet another new list of proposed amendments was published[1], this time consolidating the […]

Can Post Filing Data Overcome Inventive Step in China?

2018年11月19日
Since 2010, the Patent Re-examination Board (PRB) has published the top 10 patent invalidation cases of the year in April of each year. The selection criteria are high social concern, significant impact on the related industry, or involve difficult legal issues and important examination criteria. Below is one of the top 10 cases that discusses […]

RNAi Patent Success in China: Overcoming “Comprising” Claim Challenges

2025年3月10日
An Update on Sufficiency and Inventiveness of RNAi Patents in China RNAi is a fast-developing technology that has gained traction in the pharmaceutical industry as a promising therapeutic agent. It is important to follow closely RNAi patent proceedings to learn how different examination boards and courts understand and handle these new technologies. The first-ever invalidation […]
Top crossarrow-right